NovoCure (NVCR) Income from Continuing Operations (2014 - 2026)

NovoCure has disclosed Income from Continuing Operations across 13 years of filings, most recently posting 71138000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 71138000.0, down 107.28% year-over-year; the trailing twelve-month figure through Mar 2026 was 173046000.0 (down 5.4% YoY), and the FY2025 annual result was 136227000.0, up 19.21% from the prior year.
• Income from Continuing Operations came in at 71138000.0 for Q1 2026 at NovoCure, down from 24499000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 4647000.0 in Q1 2022 to a low of 71138000.0 in Q1 2026.
• The 5-year median for Income from Continuing Operations is 37303000.0 (2022), against an average of 39739352.94.
• Across the five-year window, Income from Continuing Operations slumped 1041.83% in 2023 and soared 62.84% in 2025, its largest moves.
• NovoCure's Income from Continuing Operations stood at 37303000.0 in 2022, then dropped by 26.21% to 47079000.0 in 2023, then plunged by 40.02% to 65922000.0 in 2024, then jumped by 62.84% to 24499000.0 in 2025, then tumbled by 190.37% to 71138000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 71138000.0 (Q1 2026), 24499000.0 (Q4 2025), and 37270000.0 (Q3 2025), per Business Quant data.